Ondine Biomedical (LSE:OBI) Debt-to-Equity : 0.18 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical Debt-to-Equity?

Ondine Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.24 Mil. Ondine Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.20 Mil. Ondine Biomedical's Total Stockholders Equity for the quarter that ended in Jun. 2023 was £2.47 Mil. Ondine Biomedical's debt to equity for the quarter that ended in Jun. 2023 was 0.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ondine Biomedical's Debt-to-Equity or its related term are showing as below:

LSE:OBI' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.65 Med: -0.91 Max: 0.18
Current: 0.18

During the past 13 years, the highest Debt-to-Equity Ratio of Ondine Biomedical was 0.18. The lowest was -1.65. And the median was -0.91.

LSE:OBI's Debt-to-Equity is ranked worse than
53.09% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs LSE:OBI: 0.18

Ondine Biomedical Debt-to-Equity Historical Data

The historical data trend for Ondine Biomedical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Debt-to-Equity Chart

Ondine Biomedical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-1.17

-1.08

-0.93

0.03

0.08

Ondine Biomedical Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															-0.91	0.03	0.03	0.08	0.18

Competitive Comparison of Ondine Biomedical's Debt-to-Equity

For the Biotechnology subindustry, Ondine Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ondine Biomedical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Debt-to-Equity falls into.

Ondine Biomedical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ondine Biomedical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.217	+	0.325)	/	7.037
	=	0.08

Ondine Biomedical's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.239	+	0.196)	/	2.471
	=	0.18

Ondine Biomedical (LSE:OBI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ondine Biomedical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ondine Biomedical (LSE:OBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

OBIMF:USA

Address

1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6

Website

https://www.ondinebio.com

Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical (LSE:OBI) Headlines

No Headlines